review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | A. Brice | |
S. Lesage | |||
P2860 | cites work | Interface between tauopathies and synucleinopathies: A tale of two proteins | Q22252940 |
High-resolution whole-genome association study of Parkinson disease. | Q24535861 | ||
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies | Q24653247 | ||
Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease | Q24656075 | ||
Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36 | Q24680678 | ||
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
Alpha-synuclein in Lewy bodies | Q27860680 | ||
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase | Q28116395 | ||
Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice | Q28208193 | ||
Glucocerebrosidase mutations in subjects with parkinsonism | Q28239212 | ||
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications | Q28241852 | ||
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease | Q28257086 | ||
Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling | Q28505191 | ||
Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice | Q28507648 | ||
Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data | Q28943545 | ||
The LRRK2 Arg1628Pro variant is a risk factor for Parkinson's disease in the Chinese population | Q46619827 | ||
Essential tremor and the common LRRK2 G2385R variant | Q46721342 | ||
Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. | Q46854860 | ||
Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population | Q46943278 | ||
Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism | Q46960409 | ||
Neuropathology provides clues to the pathophysiology of Gaucher disease | Q47247270 | ||
The parkinsonian phenotype of spinocerebellar ataxia type 2. | Q47254835 | ||
Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients | Q47587717 | ||
Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation | Q48109654 | ||
Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population | Q48266604 | ||
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication | Q48298527 | ||
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease | Q48392751 | ||
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders | Q48491146 | ||
Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation | Q48784105 | ||
Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's disease | Q50280082 | ||
The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease. | Q51731132 | ||
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. | Q53249928 | ||
alpha-Synuclein gene duplication is present in sporadic Parkinson disease. | Q53473267 | ||
Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. | Q53532682 | ||
Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplication | Q46318649 | ||
Lrrk2 R1628P in non-Chinese Asian races | Q46439311 | ||
Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms | Q46583182 | ||
Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation | Q46587417 | ||
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 | ||
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease | Q29614762 | ||
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
Lack of replication of association between GIGYF2 variants and Parkinson disease. | Q30437358 | ||
Genomewide association study for susceptibility genes contributing to familial Parkinson disease | Q30437480 | ||
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study | Q30440660 | ||
Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls | Q30440991 | ||
Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease | Q30483458 | ||
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). | Q30938617 | ||
Multiple regions of alpha-synuclein are associated with Parkinson's disease | Q31155710 | ||
Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. | Q33226010 | ||
Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data | Q33226682 | ||
A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan | Q33267533 | ||
Meta-analysis in genome-wide association datasets: strategies and application in Parkinson disease | Q33276409 | ||
Beyond Parkinson disease: amyotrophic lateral sclerosis and the axon guidance pathway | Q33314917 | ||
Analysis of the LRRK2 Gly2385Arg variant in primary dystonia and multiple system atrophy in Taiwan | Q33331261 | ||
LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson's disease compared to late-onset patients | Q33340326 | ||
Neither replication nor simulation supports a role for the axon guidance pathway in the genetics of Parkinson's disease | Q33352050 | ||
Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. | Q33377437 | ||
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders | Q33677320 | ||
Significant linkage of Parkinson disease to chromosome 2q36-37 | Q33904993 | ||
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations | Q33942173 | ||
CAG repeat instability at SCA2 locus: anchoring CAA interruptions and linked single nucleotide polymorphisms | Q34100075 | ||
SCA2 may present as levodopa-responsive parkinsonism | Q34187852 | ||
Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews | Q34365028 | ||
A susceptibility locus for Parkinson's disease maps to chromosome 2p13. | Q34460129 | ||
Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease | Q34565111 | ||
PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron | Q34568479 | ||
ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease | Q34626200 | ||
The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? | Q34701291 | ||
Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin | Q34892238 | ||
LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. | Q35070498 | ||
Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen | Q35117445 | ||
Present and future drug treatment for Parkinson's disease | Q35484805 | ||
Growth hormone treatment in short Japanese children born small for gestational age. | Q35946649 | ||
Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese | Q36227499 | ||
How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease | Q36310520 | ||
Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays | Q36719174 | ||
Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations | Q36748778 | ||
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease | Q36761674 | ||
Deciphering the role of heterozygous mutations in genes associated with parkinsonism | Q36854642 | ||
Genetic variation of Omi/HtrA2 and Parkinson's disease | Q37037500 | ||
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease | Q37054679 | ||
The utility F-box for protein destruction | Q37111318 | ||
Non-motor symptoms in Parkinson's disease | Q37114116 | ||
Neurodegeneration associated with genetic defects in phospholipase A(2). | Q37179015 | ||
Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations | Q37361830 | ||
Genomic investigation of alpha-synuclein multiplication and parkinsonism | Q37362778 | ||
Genetic anticipation in Parkinson's disease | Q38509730 | ||
Genetic screening of the G2019S mutation of the LRRK2 gene in Southwest European, North African, and Sephardic Jewish subjects | Q38938687 | ||
LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study | Q39086510 | ||
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families | Q39095724 | ||
Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease? | Q39171885 | ||
G2019S LRRK2 mutation in French and North African families with Parkinson's disease | Q39171895 | ||
A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease | Q39579467 | ||
The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. | Q40074115 | ||
Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease | Q40102731 | ||
LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China | Q40133563 | ||
Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. | Q40210208 | ||
The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. | Q40223841 | ||
Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia | Q40251831 | ||
Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system | Q40761847 | ||
Neuropathology of Parkinson's disease | Q41095404 | ||
Considerations for genomewide association studies in Parkinson disease | Q42418603 | ||
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease | Q42628290 | ||
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease | Q42675021 | ||
The LRRK2 gene in Parkinson's disease: mutation screening in patients from Germany | Q42765219 | ||
LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century | Q43004241 | ||
The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. | Q43560873 | ||
Prevalence of spinocerebellar ataxia type 2 mutation among Italian Parkinsonian patients | Q44009968 | ||
Polymorphisms of the alpha-synuclein promoter: expression analyses and association studies in Parkinson's disease | Q44286639 | ||
The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson's disease | Q44594403 | ||
New genetic insights into Parkinson's disease | Q45138677 | ||
Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families | Q45219624 | ||
Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease | Q46233748 | ||
Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore | Q46241226 | ||
Presence of spinocerebellar ataxia type 2 gene mutation in a patient with apparently sporadic Parkinson's disease: clinical implications. | Q53610557 | ||
Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. | Q54537164 | ||
Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. | Q54626622 | ||
LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. | Q54697490 | ||
alpha-Synuclein promoter confers susceptibility to Parkinson's disease. | Q54699461 | ||
LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. | Q55041570 | ||
Alpha-synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patients | Q56637598 | ||
PARK9-LINKED PARKINSONISM IN EASTERN ASIA: MUTATION DETECTION IN ATP13A2 AND CLINICAL PHENOTYPE | Q56772080 | ||
Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian | Q57248434 | ||
A susceptibility gene for late-onset idiopathic Parkinson's disease | Q57309530 | ||
Analysis of the glucocerebrosidase gene in Parkinson's disease | Q57318911 | ||
The Ala53Thr mutation in the α-synuclein gene in a Korean family with Parkinson disease | Q57577939 | ||
Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease | Q57623825 | ||
Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families | Q57629162 | ||
alpha-synuclein gene haplotypes are associated with Parkinson's disease | Q57905836 | ||
Are interruptedSCA2CAG repeat expansions responsible for parkinsonism? | Q57970884 | ||
Collaborative Analysis of α-Synuclein Gene Promoter Variability and Parkinson Disease | Q57977634 | ||
LRRK2 mutation in familial Parkinson’s disease in a Taiwanese population: clinical, PET, and functional studies | Q57983248 | ||
-Synuclein, pesticides, and Parkinson disease: A case-control study | Q57983254 | ||
LRRK2 mutations in Parkinson disease | Q57983290 | ||
Lrrk2 pathogenic substitutions in Parkinson's disease | Q57983291 | ||
LRRK2G2019S as a Cause of Parkinson's Disease in North African Arabs | Q58489573 | ||
A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease | Q58870346 | ||
Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr ?-synuclein mutation | Q59544661 | ||
Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism | Q60532601 | ||
Evaluation of LRRK2 G2019S penetrance: Relevance for genetic counseling in Parkinson disease | Q62128619 | ||
Analysis of LRRK2 G2019S and I2020T mutations in Parkinson's disease | Q62588920 | ||
Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease | Q64913752 | ||
LRRK2 R1628P increases risk of Parkinson's disease: replication evidence | Q64958593 | ||
Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants | Q79555494 | ||
Neurological signs: Behçet's disease, coeliac disease, both, or neither? | Q79652541 | ||
Comparing LRRK2 Gly2385Arg carriers with noncarriers | Q79751589 | ||
Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia | Q80493033 | ||
Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls | Q80535570 | ||
Analysis of LRRK2 Gly2385Arg genetic variant in non-Chinese Asians | Q80691674 | ||
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease | Q80794093 | ||
Association between Parkinson's disease and glucocerebrosidase mutations in Brazil | Q80806938 | ||
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset | Q81147302 | ||
The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease | Q81322451 | ||
Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset | Q81403790 | ||
The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews | Q81411336 | ||
The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease | Q81415949 | ||
Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's disease | Q82704418 | ||
A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan | Q83191880 | ||
Genetic analysis of SCA2, 3 and 17 in idiopathic Parkinson's disease | Q83315441 | ||
Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease | Q83941112 | ||
??? | Q64913750 | ||
P433 | issue | R1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Parkinson's disease | Q11085 |
P304 | page(s) | R48-R59 | |
P577 | publication date | 2009-04-15 | |
P1433 | published in | Human Molecular Genetics | Q2720965 |
P1476 | title | Parkinson's disease: from monogenic forms to genetic susceptibility factors | |
P478 | volume | 18 |
Q36223954 | (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. |
Q38450033 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease in zebrafish |
Q37620482 | A dual-hit animal model for age-related parkinsonism |
Q34801743 | A genome-wide linkage screen in the Amish with Parkinson disease points to chromosome 6 |
Q52322083 | A meta-analysis of public microarray data identifies biological regulatory networks in Parkinson's disease. |
Q37655091 | A network view on Parkinson's disease |
Q36020336 | A reference library of peripheral blood mononuclear cells for SWATH-MS analysis |
Q38850614 | A53T in a parkinsonian family: a clinical update of the SNCA phenotypes |
Q28119120 | ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons |
Q39516168 | ATP13A2 variability in Taiwanese Parkinson's disease |
Q37607449 | Abnormal mitochondrial dynamics and neurodegenerative diseases |
Q37779272 | Achalasia: will genetic studies provide insights? |
Q39355888 | Acute exposure to a Mn/Zn ethylene-bis-dithiocarbamate fungicide leads to mitochondrial dysfunction and increased reactive oxygen species production in Caenorhabditis elegans |
Q55667027 | Adipose-derived Stem Cells Stimulated with n-Butylidenephthalide Exhibit Therapeutic Effects in a Mouse Model of Parkinson's Disease. |
Q64768798 | Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA) |
Q38792540 | Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity |
Q93050900 | Allopregnanolone Modulates GABAAR-Dependent CaMKIIδ3 and BDNF to Protect SH-SY5Y Cells Against 6-OHDA-Induced Damage |
Q64764558 | Alpha-synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease |
Q49045276 | Alpha-synuclein transmission and mitochondrial toxicity in primary human foetal enteric neurons in vitro |
Q37066475 | An inflection point in gene discovery efforts for neurodegenerative diseases: from syndromic diagnoses toward endophenotypes and the epigenome |
Q34800195 | An overview on the correlation of neurological disorders with cardiovascular disease |
Q33911698 | Analysis of Dosage Mutation in PARK2 among Korean Patients with Early-Onset or Familial Parkinson's Disease |
Q37271108 | Analysis of LRRK2, SNCA, and ITGA8 Gene Variants with Sporadic Parkinson's Disease Susceptibility in Chinese Han Population. |
Q34992975 | Analysis of Thr12Met and Ala1144Thr mutations of the ATP13A2 gene in Parkinson's disease patients in Xinjiang Uygur and Han ethnic groups |
Q82253370 | Analysis of exon dosage using MLPA in South African Parkinson's disease patients |
Q26799331 | Applications of Induced Pluripotent Stem Cells in Studying the Neurodegenerative Diseases |
Q37598121 | Are there common biochemical and molecular mechanisms controlling manganism and parkisonism |
Q37424589 | Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis |
Q38049356 | Association of catechol-o-methyltransferase polymorphism (Val108/158Met) with Parkinson's disease: a meta-analysis |
Q40201296 | Association of four new candidate genetic variants with Parkinson's disease in a Han Chinese population |
Q35935522 | Association of three candidate genetic variants in RAB7L1/NUCKS1, MCCC1 and STK39 with sporadic Parkinson's disease in Han Chinese |
Q37645620 | Association studies of sporadic Parkinson's disease in the genomic era. |
Q47915648 | Associations of specific psychiatric disorders with isolated focal dystonia, and monogenic and idiopathic Parkinson's disease |
Q46283192 | Astragaloside IV attenuates the H2O2-induced apoptosis of neuronal cells by inhibiting α-synuclein expression via the p38 MAPK pathway |
Q38018827 | Autoimmunity, dendritic cells and relevance for Parkinson's disease |
Q39454262 | Autophagy and Human Neurodegenerative Diseases-A Fly's Perspective |
Q28273228 | Autophagy in Neurodegenerative Diseases and Metal Neurotoxicity |
Q38164897 | Autophagy in inflammation, infection, neurodegeneration and cancer |
Q37800102 | Autosomal Recessive Mutations in the Development of Parkinson‘s Disease |
Q38642565 | Back and forth in time: Directing age in iPSC-derived lineages. |
Q38203487 | Barcoding heat shock proteins to human diseases: looking beyond the heat shock response |
Q38093247 | Biomarkers for the diagnosis and management of Parkinson's disease |
Q50695868 | Biomarkers in Parkinson's disease. |
Q36616565 | COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease prog |
Q42534539 | Calcium homeostasis in aging neurons |
Q38208179 | Calcium signaling in Parkinson's disease. |
Q37085692 | Calpastatin gene (CAST) is not associated with late onset sporadic Parkinson's disease in the Han Chinese population |
Q35875886 | Cause or Effect: Misregulation of microRNA Pathways in Neurodegeneration |
Q28080770 | Cell reprogramming and neuronal differentiation applied to neurodegenerative diseases: Focus on Parkinson's disease |
Q93138854 | Cell therapy for Parkinson's disease is coming of age: current challenges and future prospects with a focus on immunomodulation |
Q38021569 | Cellular and molecular mechanisms of antioxidants in Parkinson's disease |
Q90714057 | Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson's disease |
Q38553329 | Chaperone-mediated autophagy and neurodegeneration: connections, mechanisms, and therapeutic implications |
Q35795120 | Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants |
Q41996686 | Chronic stress enhances microglia activation and exacerbates death of nigral dopaminergic neurons under conditions of inflammation. |
Q41863382 | Classification of Parkinson's Disease Genotypes in Drosophila Using Spatiotemporal Profiling of Vision |
Q64929400 | Combined accelerometer and genetic analysis to differentiate essential tremor from Parkinson's disease. |
Q36613610 | Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for Parkinson's disease |
Q34409499 | Concise review: Patient-derived olfactory stem cells: new models for brain diseases |
Q35234940 | Construction and analysis of the protein-protein interaction networks based on gene expression profiles of Parkinson's disease |
Q37970303 | Control of autophagy as a therapy for neurodegenerative disease |
Q23914777 | Correlation between the biochemical pathways altered by mutated Parkinson-related genes and chronic exposure to manganese |
Q36533944 | Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide |
Q38433683 | DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease |
Q27312297 | DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient |
Q35290033 | Decreased expression of B cell related genes in leukocytes of women with Parkinson's disease |
Q44617144 | Decreased expression of lysosomal alpha-galactosiase A gene in sporadic Parkinson's disease. |
Q36020884 | Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations |
Q36025246 | Development of stem cell-based therapy for Parkinson's disease |
Q64104013 | Differentiation of adult human retinal pigment epithelial cells into dopaminergic-like cells in vitro and in the recipient monkey brain |
Q41964090 | Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. |
Q29248297 | Disease-toxicant interactions in Parkinson's disease neuropathology |
Q33940936 | Disruption of LRRK2 does not cause specific loss of dopaminergic neurons in zebrafish |
Q61449551 | Distinct Stress Response and Altered Striatal Transcriptome in Alpha-Synuclein Overexpressing Mice |
Q38067885 | Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology? |
Q36002833 | Dopamine-derived quinones affect the structure of the redox sensor DJ-1 through modifications at Cys-106 and Cys-53 |
Q41117800 | Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects |
Q36680414 | Drug discovery in Parkinson's disease-Update and developments in the use of cellular models |
Q28073686 | Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases |
Q41317700 | Early Onset Parkinson's Disease in a family of Moroccan origin caused by a p.A217D mutation in PINK1: a case report |
Q58582532 | Early-onset Parkinson disease caused by a mutation in CHCHD2 and mitochondrial dysfunction |
Q42723659 | Effects of balance and gait training on the recovery of the motor function in an animal model of Parkinson's disease |
Q43577652 | Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. |
Q38598842 | Emerging bioinformatics approaches for analysis of NGS-derived coding and non-coding RNAs in neurodegenerative diseases. |
Q37654778 | Emerging roles of Wnts in the adult nervous system |
Q37926552 | Emerging roles of epigenetic mechanisms in Parkinson's disease |
Q38502761 | Emotional dysfunctions in neurodegenerative diseases. |
Q24293694 | Endoplasmic reticulum stress and Parkinson's disease: the role of HRD1 in averting apoptosis in neurodegenerative disease |
Q24630696 | Enhancing CNS repair in neurological disease: challenges arising from neurodegeneration and rewiring of the network |
Q28074723 | Environmental Exposures and Parkinson's Disease |
Q92316611 | Evaluation of the Common Molecular Basis in Alzheimer's and Parkinson's Diseases |
Q39214168 | Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study |
Q35668490 | Exonic Re-Sequencing of the Chromosome 2q24.3 Parkinson's Disease Locus |
Q55617564 | Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy. |
Q38079242 | Exosomes-associated neurodegeneration and progression of Parkinson's disease |
Q37809870 | Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities |
Q39428788 | Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review. |
Q33955534 | Familial associations of Alzheimer disease and essential tremor with Parkinson disease |
Q30995743 | Family-based genome scan for age at onset of late-onset Alzheimer's disease in whole exome sequencing data |
Q35846517 | Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples |
Q36745293 | Focusing brain therapeutic interventions in space and time for Parkinson's disease |
Q23920397 | From manganism to manganese-induced parkinsonism: a conceptual model based on the evolution of exposure |
Q37578490 | Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease |
Q36777244 | GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A. |
Q37979978 | Gaucher disease and the synucleinopathies: refining the relationship |
Q35851610 | Gaucher-Associated Parkinsonism |
Q28388674 | Gene-environment interactions: key to unraveling the mystery of Parkinson's disease |
Q36050210 | Genetic Mutation Analysis of Parkinson's Disease Patients Using Multigene Next-Generation Sequencing Panels. |
Q26768278 | Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson's Disease |
Q38637878 | Genetic Variants in SNCA and the Risk of Sporadic Parkinson's Disease and Clinical Outcomes: A Review |
Q35712293 | Genetic Variants of SNCA Are Associated with Susceptibility to Parkinson's Disease but Not Amyotrophic Lateral Sclerosis or Multiple System Atrophy in a Chinese Population |
Q34996445 | Genetic analysis of the FBXO42 gene in Chinese Han patients with Parkinson's disease |
Q34234597 | Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome |
Q37328854 | Genetic association of NOS1 exon18, NOS1 exon29, ABCB1 1236C/T, and ABCB1 3435C/T polymorphisms with the risk of Parkinson's disease: A meta-analysis |
Q44358768 | Genetic bases and phenotypes of autosomal recessive Parkinson disease in a Turkish population |
Q94586186 | Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson's disease pathogenesis |
Q94465937 | Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells |
Q39253264 | Genetic risk for Parkinson's disease correlates with alterations in neuronal manganese sensitivity between two human subjects |
Q27022109 | Genetics of Parkinson's disease - a clinical perspective |
Q34898429 | Gene–Environment Interactions in Parkinson's Disease: The Importance of Animal Modeling |
Q58764784 | Genome Editing of Pigs for Agriculture and Biomedicine |
Q84485275 | Genome-wide association studies: the key to unlocking neurodegeneration? |
Q24596763 | Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease |
Q51620290 | Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. |
Q33991709 | Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes |
Q36513434 | Glucocerebrosidase L444P mutation confers genetic risk for Parkinson's disease in central China |
Q43823053 | HLA-DRA is associated with Parkinson's disease in Iranian population. |
Q92448054 | Han Chinese family with early-onset Parkinson's disease carries novel compound heterozygous mutations in the PARK2 gene |
Q43215480 | Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications |
Q35675965 | Heritability of Parkinson disease in Swedish twins: a longitudinal study |
Q50254943 | High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson's disease. |
Q40658284 | High-resolution arrays reveal burden of copy number variations on Parkinson disease genes associated with increased disease risk in random cohorts |
Q43921081 | How parkinsonism influences life: the patients' point of view |
Q38168763 | Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development |
Q38503340 | Identification of Parkinson's disease candidate genes using CAESAR and screening of MAPT and SNCAIP in South African Parkinson's disease patients |
Q34279026 | Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregation |
Q28743569 | Identification of allele-specific RNAi effectors targeting genetic forms of Parkinson's disease |
Q34449994 | Identification of key pathways and transcription factors related to Parkinson disease in genome wide |
Q38184645 | Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders |
Q30397945 | In Silico Analysis of SNPs in PARK2 and PINK1 Genes That Potentially Cause Autosomal Recessive Parkinson Disease. |
Q24655848 | Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein |
Q35812803 | Increased Transcript Complexity in Genes Associated with Chronic Obstructive Pulmonary Disease |
Q38737027 | Induced pluripotent stem cell-based modeling of neurodegenerative diseases: a focus on autophagy. |
Q26771402 | Induced pluripotent stem cells for modeling neurological disorders |
Q35687315 | Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons |
Q55497257 | Integrated Analysis and Identification of Novel Biomarkers in Parkinson's Disease. |
Q35899904 | Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease |
Q36116735 | Intelligence: shared genetic basis between Mendelian disorders and a polygenic trait |
Q36489290 | Interaction between RING1 (R1) and the Ubiquitin-like (UBL) Domains Is Critical for the Regulation of Parkin Activity |
Q37577611 | Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease. |
Q35585714 | Interleukin-1 receptor antagonist reduces neonatal lipopolysaccharide-induced long-lasting neurobehavioral deficits and dopaminergic neuronal injury in adult rats |
Q38103856 | Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease? |
Q38817063 | Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease. |
Q34093439 | Iron transport in Parkinson's disease |
Q35158376 | Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases? |
Q41577935 | Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP+-dependent isocitrate dehydrogenase (IDH). |
Q34145889 | L10p and P158DEL DJ‐1 mutations cause protein instability, aggregation, and dimerization impairments |
Q64791386 | LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease |
Q42873469 | LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß. |
Q33603103 | LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients |
Q42927984 | LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity |
Q26861279 | LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson's Disease |
Q24307455 | LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study |
Q24301357 | LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1 |
Q38389768 | Lack of association between the ATP13A2 A746T variant and Parkinson's disease susceptibility in Han Chinese: a meta-analysis |
Q35754683 | Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease |
Q55240777 | Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease. |
Q88643636 | Long Non-Coding RNAs in Multifactorial Diseases: Another Layer of Complexity |
Q28109404 | Manganese Homeostasis and Transport |
Q36223221 | Manganese-induced toxicity in normal and human B lymphocyte cell lines containing a homozygous mutation in parkin. |
Q39465478 | Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease |
Q28394732 | Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease |
Q37043326 | Membrane trafficking in neuronal maintenance and degeneration. |
Q37090660 | Mendelian Randomization - the Key to Understanding Aspects of Parkinson's Disease Causation? |
Q53245195 | Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease. |
Q36128123 | Meta-Analysis of Parkinson's Disease Transcriptome Data Using TRAM Software: Whole Substantia Nigra Tissue and Single Dopamine Neuron Differential Gene Expression. |
Q38109630 | Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures |
Q47102033 | MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease. |
Q36640417 | Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein |
Q89462541 | Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice |
Q34292484 | Microtubule destabilization is shared by genetic and idiopathic Parkinson's disease patient fibroblasts |
Q90457655 | Misfolded Protein Linked Strategies Toward Biomarker Development for Neurodegenerative Diseases |
Q37889815 | Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease |
Q28280353 | Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease |
Q38237889 | Mitochondrial dynamic changes in health and genetic diseases |
Q36365785 | Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders |
Q37587126 | Mitophagy and Parkinson's disease: the PINK1-parkin link. |
Q60919555 | Modeling Parkinson's Disease and Atypical Parkinsonian Syndromes Using Induced Pluripotent Stem Cells |
Q38005912 | Modeling Parkinson's disease using induced pluripotent stem cells |
Q58114516 | Models of Sporadic Parkinson's Disease |
Q34014651 | Modest CaV1.342-selective inhibition by compound 8 is β-subunit dependent |
Q36872325 | Modulating the Amyloidogenesis of α-Synuclein |
Q37749063 | Molecular mechanisms of pathogenesis of Parkinson's disease. |
Q37968084 | Molecular pathways in sporadic PD. |
Q37679384 | Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease |
Q34100399 | Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review |
Q38112215 | Network modeling to identify new mechanisms and therapeutic targets for Parkinson's disease |
Q27021719 | Neural stem cells could serve as a therapeutic material for age-related neurodegenerative diseases |
Q58737028 | Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches |
Q37668234 | Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms |
Q90359231 | Neurodegenerative diseases: model organisms, pathology and autophagy |
Q37538771 | Neurodegenerative disorders and nanoformulated drug development |
Q34234625 | Neuroimaging: current role in detecting pre-motor Parkinson's disease. |
Q26765693 | Neuroprotective Transcription Factors in Animal Models of Parkinson Disease |
Q36333141 | Neurosupportive Role of Vanillin, a Natural Phenolic Compound, on Rotenone Induced Neurotoxicity in SH-SY5Y Neuroblastoma Cells |
Q37951958 | New animal models of Parkinson's disease |
Q38430373 | New insights on Parkinson's disease genes: the link between mitochondria impairment and neuroinflammation |
Q38263132 | No evidence of association between common European mitochondrial DNA variants in Alzheimer, Parkinson, and migraine in the Spanish population |
Q47805564 | No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease in nine ADHD candidate SNPs. |
Q35544534 | Novel variant Pro143Ala in HTRA2 contributes to Parkinson's disease by inducing hyperphosphorylation of HTRA2 protein in mitochondria. |
Q36732766 | Nrf2--a therapeutic target for the treatment of neurodegenerative diseases |
Q57073168 | Nucleolar Disruption in Dopaminergic Neurons Leads to Oxidative Damage and Parkinsonism through Repression of Mammalian Target of Rapamycin Signaling |
Q36560195 | One-step generation of triple gene-targeted pigs using CRISPR/Cas9 system |
Q37509229 | Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle |
Q47102647 | PARK14 PLA2G6 mutants are defective in preventing rotenone-induced mitochondrial dysfunction, ROS generation and activation of mitochondrial apoptotic pathway. |
Q42183671 | ParkDB: a Parkinson's disease gene expression database |
Q37337917 | Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation |
Q27340039 | Parkin promotes proteasomal degradation of p62: implication of selective vulnerability of neuronal cells in the pathogenesis of Parkinson's disease |
Q34719767 | Parkin ubiquitinates Drp1 for proteasome-dependent degradation: implication of dysregulated mitochondrial dynamics in Parkinson disease |
Q37972057 | Parkin: much more than a simple ubiquitin ligase |
Q52559939 | Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process. |
Q39714333 | Parkinson disease-associated DJ-1 is required for the expression of the glial cell line-derived neurotrophic factor receptor RET in human neuroblastoma cells. |
Q42562656 | Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything? |
Q34245014 | Parkinson's disease DJ-1 L166P alters rRNA biogenesis by exclusion of TTRAP from the nucleolus and sequestration into cytoplasmic aggregates via TRAF6 |
Q30438194 | Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance |
Q37633575 | Parkinson's disease, autoimmunity, and olfaction |
Q34140428 | Parkinson's disease: Exit toxins, enter genetics |
Q52709039 | Parkinson's disease: Role of genetic and environment factors. Involvement in everyday clinical practice |
Q33871291 | Parkinson's disease: insights from pathways |
Q92155477 | Peroxiredoxin 5 Silencing Sensitizes Dopaminergic Neuronal Cells to Rotenone via DNA Damage-Triggered ATM/p53/PUMA Signaling-Mediated Apoptosis |
Q37957393 | Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease |
Q34181728 | Phase analysis identifies compound heterozygous deletions of the PARK2 gene in patients with early-onset Parkinson disease |
Q36120753 | Phenome-based gene discovery provides information about Parkinson's disease drug targets |
Q42338923 | Phenotypic Discordance in Siblings with Identical Compound Heterozygous PARK2 Mutations |
Q48246699 | Phosphorylated α-Synuclein-Copper Complex Formation in the Pathogenesis of Parkinson's Disease |
Q54603565 | Phylogenetic and in silico structural analysis of the Parkinson disease-related kinase PINK1. |
Q36891717 | Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease |
Q27322563 | Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease. |
Q37129378 | Potential Role of Caffeine in the Treatment of Parkinson's Disease |
Q38629277 | Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease |
Q47322162 | Predicting phenotypes from microarrays using amplified, initially marginal, eigenvector regression |
Q36444517 | Premotor biomarkers for Parkinson's disease - a promising direction of research |
Q64082784 | Prioritizing Parkinson's disease genes using population-scale transcriptomic data |
Q37717607 | Progressive degeneration of dopaminergic neurons through TRP channel-induced cell death. |
Q38091029 | Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis. |
Q35080559 | Proteins in aggregates functionally impact multiple neurodegenerative disease models by forming proteasome-blocking complexes |
Q39639654 | Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis |
Q26800109 | Psychological Benefits of Nonpharmacological Methods Aimed for Improving Balance in Parkinson's Disease: A Systematic Review |
Q34189660 | Recent advances in the genetics of Parkinson's disease |
Q42239663 | Redox regulation of cysteine-dependent enzymes in neurodegeneration |
Q26751786 | Research in Parkinson's disease in India: A review |
Q56558187 | Restoration of motor control and dopaminergic activity in rats with unilateral 6-hydroxy-dopamine lesions |
Q43375939 | Resveratrol Modulation of Protein Expression in parkin-Mutant Human Skin Fibroblasts: A Proteomic Approach |
Q37844489 | Revisiting Mendelian disorders through exome sequencing |
Q38659590 | Role of Apolipoproteins and α-Synuclein in Parkinson's Disease. |
Q38805953 | Role of Endoplasmic Reticulum Stress and Unfolded Protein Responses in Health and Diseases |
Q34240463 | Role of mendelian genes in "sporadic" Parkinson's disease |
Q36001692 | Rotenone Susceptibility Phenotype in Olfactory Derived Patient Cells as a Model of Idiopathic Parkinson's Disease |
Q35859538 | SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population |
Q57983208 | SNCA,MAPT, andGSK3Bin Parkinson disease: a gene-gene interaction study |
Q37779808 | Safinamide in the treatment of Parkinson's disease |
Q38899693 | Salsolinol Damaged Neuroblastoma SH-SY5Y Cells Induce Proliferation of Human Monocyte THP-1 Cells Through the mTOR Pathway in a Co-culture System |
Q50167571 | Selective dopaminergic neurotoxicity of three heterocyclic amine subclasses in primary rat midbrain neurons. |
Q38199451 | Selenium and selenoprotein function in brain disorders |
Q52313428 | Self-administration of methamphetamine alters gut biomarkers of toxicity. |
Q56381130 | Sex-Specific Transcriptome Differences in Substantia Nigra Tissue: A Meta-Analysis of Parkinson's Disease Data |
Q58784650 | Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders |
Q33666819 | Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene |
Q46047010 | Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease |
Q38657861 | Sodium benzoate, a metabolite of cinnamon and a food additive, upregulates neuroprotective Parkinson disease protein DJ-1 in astrocytes and neurons |
Q46242053 | Stearic acid supplementation in high protein to carbohydrate (P:C) ratio diet improves physiological and mitochondrial functions of Drosophila melanogaster parkin null mutants |
Q45143202 | Structural and functional in silico analysis of LRRK2 missense substitutions |
Q33701172 | Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease |
Q35682515 | Studies of protein aggregation in A53T α-synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice. |
Q27026829 | Synaptic dysfunction and septin protein family members in neurodegenerative diseases |
Q37802464 | Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy? |
Q24302024 | Synaptic vesicle trafficking and Parkinson's disease |
Q34109658 | Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms |
Q48125960 | TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson's disease brains. |
Q41867906 | Targeting the low-hanging fruit of neurodegeneration |
Q38024715 | The "Janus-faced role" of autophagy in neuronal sickness: focus on neurodegeneration |
Q30357944 | The Monoamine Brainstem Reticular Formation as a Paradigm for Re-Defining Various Phenotypes of Parkinson's Disease Owing Genetic and Anatomical Specificity. |
Q26822972 | The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases |
Q40202718 | The Potential Mutation of GAK Gene in the Typical Sporadic Parkinson's Disease from the Han Population of Chinese Mainland. |
Q52327330 | The Retromer Complex and Sorting Nexins in Neurodegenerative Diseases. |
Q38026044 | The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease |
Q38482479 | The Role of α-Synuclein and LRRK2 in Tau Phosphorylation |
Q38093808 | The VPS35 gene and Parkinson's disease |
Q37369346 | The association between Parkinson's disease and anti-epilepsy drug carbamazepine: a case-control study using the UK General Practice Research Database |
Q37845675 | The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease |
Q38998036 | The effects of morphine on Parkinson's-related genes PINK1 and PARK2. |
Q34557246 | The endotoxin-induced neuroinflammation model of Parkinson's disease. |
Q47646796 | The genetic architecture of mitochondrial dysfunction in Parkinson's disease |
Q34513714 | The genetic background of Parkinson's disease: current progress and future prospects |
Q34604083 | The genetics of Parkinson disease |
Q28543195 | The high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease |
Q37111847 | The mitochondrial dynamics of Alzheimer's disease and Parkinson's disease offer important opportunities for therapeutic intervention |
Q28117293 | The parkin-like human homolog of Drosophila ariadne-1 (HHARI) can induce aggresome formation in mammalian cells and is immunologically detectable in Lewy bodies |
Q28077257 | The relationship between glucocerebrosidase mutations and Parkinson disease |
Q37646362 | The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease |
Q38166155 | The role of innate and adaptive immunity in Parkinson's disease |
Q38290759 | Therapeutic strategies in Parkinson's disease: what we have learned from animal models |
Q39273083 | Transcriptome Profile Changes in Mice with MPTP-Induced Early Stages of Parkinson's Disease |
Q33614776 | Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease |
Q37897498 | Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system |
Q42173591 | Ubiquitin ligase parkin promotes Mdm2-arrestin interaction but inhibits arrestin ubiquitination |
Q39067542 | Ultrasound-based motion analysis demonstrates bilateral arm hypokinesia during gait in heterozygous PINK1 mutation carriers |
Q37555526 | Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions |
Q37896718 | Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders |
Q35008102 | Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts |
Q92824874 | VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson's disease |
Q50254001 | VPS35 mutation in Japanese patients with typical Parkinson's disease |
Q35327512 | Vitamin D from different sources is inversely associated with Parkinson disease |
Q36315569 | Whole genome expression profile in neuroblastoma cells exposed to 1-methyl-4-phenylpyridine |
Q28771729 | Widespread macromolecular interaction perturbations in human genetic disorders |
Q44012668 | YY1 binds to α-synuclein 3'-flanking region SNP and stimulates antisense noncoding RNA expression. |
Q38247942 | Zinc Finger Nucleases: A new era for transgenic animals |
Q38742153 | α-Synuclein and Parkinsonism: Updates and Future Perspectives |
Q64866429 | α-Synuclein and Polyunsaturated Fatty Acids: Molecular Basis of the Interaction and Implication in Neurodegeneration |
Q35100189 | α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease |
Q38912683 | α-Synuclein-carrying extracellular vesicles in Parkinson's disease: deadly transmitters |
Q84539110 | β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease |